Artax Biopharma Inc’s Post

At Artax Biopharma, we are developing first-in-class Nck modulators to treat T cell mediated autoimmune disease such as #psoriasis, #atopicdermatitis, and more. We're excited by the progress we've been making in the development of our first novel mechanism, AX-158, as we rapidly approach phase 2 trials for psoriasis treatment with first results expected in Q4 2024. We are simultaneously developing additional Nck modulator candidates for #autoimmunediseases with AX-194 undergoing preclinical testing to enter Phase 1 trials. Learn more about our candidate pipeline on our recently updated website here: https://lnkd.in/eqq3eSTK #clinincaltrials #immunology

📢 Promising Drug Blocks Epstein Barr Virus Diseases 🌟 Hornet Therapeutics, a spin-out from the University of Basel, has published first data on its preclinical IDO1 blocker HTX-201. They aim to start clinical tests within the next 12 to 18 months to target post-transplant lymphoproliferative disease. 🏥 This small molecule drug has the potential to block a target used by the Epstein Barr virus to cause diseases. 🦠 #BioprocessUpdates #HornetTherapeutics #EBV #diseaseblocker #HTX201 #clinicaltests #posttransplantlymphoproliferativedisease #smallmoleculedrug #EpsteinBarrvirus #preclinicaldata #UniversityofBasel #virusrelateddiseases #antiviraltherapy #medicalresearch #transplantmedicine #innovationinmedicine ▷ Read the full article here: 📎 https://lnkd.in/dSTEbP3u

Forbion is thrilled to support portfolio company SynOx Therapeutics as it advances in the fight against Tenosynovial Giant Cell Tumour (TGCT), a rare and debilitating disease. The company announced the completion of an extension to its Series B financing, bringing the total raised to an impressive $92 million. This funding is advancing the TANGENT study, SynOx’s pivotal Phase 3 clinical trial for emactuzumab, a CSF-1 receptor (CSF-1R) inhibiting monoclonal antibody that has the potential to be best-in-class for TGCT treatment. The TANGENT study has officially dosed its first patients and will be conducted globally across multiple centers. With a rigorous, randomized, double-blind, placebo-controlled design, the trial will evaluate overall response rate, functional and quality of life improvements, tumour volume impact, and response duration in approximately 130 patients. We are inspired by SynOx’s commitment to transforming TGCT treatment and look forward to sharing updates from this promising trial. For more details about TANGENT go to ClinicalTrials.gov identifier: NCT05417789 Click on the following link to learn more: https://lnkd.in/eHANaNMc #Forbion #SynOxTherapeutics #SeriesB #TGCT #Biotech #ClinicalTrials #HealthcareInnovation #lifesciences #biotech Dirk Kersten Audrey Cacaly

#Congratulations 🎊 to #BIAMember Accession Therapeutics Limited who have filed an application for a first-in-human trial of TROCEPT-01 ➡️ https://ow.ly/eF6L50TmbVk TROCEPT-01 is a leading #Anticancer #immunotherapy, designed to showcase the program in solid tumours and provide clinical validation of the #TROCEPT platform 👏 Their team focused on getting TROCEPT-01, encoding a clinically validated immune #checkpoint ✅ inhibitor (ICI) transgene and with the potential to expand the success of ICIs through high tumour-localised production, to the clinic as efficiently as possible 🚀

On October 10, 2024, the Food and Drug Administration approved inavolisib (Itovebi, Genentech, Inc.) with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic #breastcancer, as detected by an #FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. FDA also approved the FoundationOne Liquid CDx assay as a companion diagnostic device to identify patients with breast cancer for treatment with inavolisib with palbociclib and fulvestrant. FDA #precisionmedicine #cancercare

#CytoAgents is developing innovative pharmaceutical products to treat life-threatening conditions, diseases, and disorders associated with Cytokine Release Syndrome (CRS), commonly referred to as cytokine storm. CRS is caused by excessive cytokine production and can be triggered by multiple diseases and treatments. Certain advanced immunotherapies in the oncology space such as CAR T-cell and Bispecific Antibody Therapies suffer from high incidence of associated CRS. Effective CRS management will support greater accessibility to and broader adoption of these highly effective therapies in the clinic. Learn more about CytoAgents' mission here: https://cytoagents.com/ #cytokinereleasesyndrome #crs #cytokines #cytokinestorm Teresa Whalen, RPh

1. PharmAust has rebranded as Neurizon Therapeutics, seeing a share price increase of approximately 90% year-to-date. 2. The company is advancing its lead drug, monepantel, now called NUZ-001, targeting neurodegenerative diseases, starting with ALS. 3. A Phase 2/3 clinical trial for NUZ-001 is set to begin in Q1 2025 as part of the HEALEY ALS Platform Trial. 4. NUZ-001 has received orphan drug designation from the FDA, providing benefits such as tax credits and market exclusivity. 5. The drug inhibits the mTOR pathway to help clear misfolded proteins in ALS, potentially slowing disease progression. 6. Early results from trials show NUZ-001 may reduce ALS symptom decline by 39% and improve patient survival rates significantly. 7. The market for ALS therapies exceeds $2 billion annually, with a high demand for effective treatments due to the lack of current cures. 8. Neurizon's strategy focuses on improving patient access, partnering with neurologists, and exploring the drug's potential for other neurodegenerative diseases.

C4d is a product of Classical pathway complement activation and has the potential to detect patients with antibody-mediated disease. The development of new therapeutics that block complement activation makes C4d a biomarker with potential to identify and monitor patients who may possibly benefit from these drugs. Learn more! https://hubs.ly/Q02Kyfs40 #complement #complementsystem #drugdevelopment #clinicalassays #ELISA #functionalassay #C4d #transplant #autoimmunity

🚨Important Update for Indian Researchers in Immunology and Complement Pathway Studies 🚨 We are excited to announce a significant advancement from our principal partner, Svar Life Science AB! The C4d biomarker, a product of Classical pathway complement activation, shows great potential in identifying patients with auto-immune diseases. With the emergence of new therapeutics that block complement activation, C4d can play a crucial role in monitoring patients who may benefit from these treatments. At BTL Biotechno Labs Pvt Ltd, we are proud to offer the C4d Complement Assay in India, providing our scientific community with cutting-edge technologies for groundbreaking research. 🔗 For more details or to inquire about how this can support your research, get in touch with us at [email protected] #Complement #Immunology #ComplementPathway #C4dBiomarker #C4dassaykit #Biotechnolabs #svar #IndianScientists #ScientificAdvances Martin Sjunnesson Nour Adilien

iRegene Receives IND approval from U.S. FDA to Start Clinical Trial for Parkinson’s Disease - https://lnkd.in/gbKS7Z8M On June 20 (UTC-4), the U.S. Food and Drug Administration (FDA) approved the IND application for NouvNeu001, a cell therapy product from iRegene Therapeutics targeting Parkinson’s Disease. This marks a significant milestone as NouvNeu001 becomes the world’s first chemically induced allogeneic cell therapy product to enter clinical stages for Parkinson’s disease in the US. Previously, the “Combined Phase I/II Clinical Study” of NouvNeu001 had already received approval from China NMPA in August 2023 and demonstrated positive safety and efficacy data in its Phase I trials. On June 20, 2024, iRegene further announced IND approval of NouvNeu001 by the U.S. FDA for the treatment of mid-to-late stage of Parkinson’s disease. Read more at: https://lnkd.in/gbKS7Z8M #parkinsonsdisease #regenerativemedicine #stemcell